Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody
Ist Teil von
mAbs, 2020-01, Vol.12 (1), p.1831880
Ort / Verlag
United States: Taylor & Francis
Erscheinungsjahr
2020
Quelle
Taylor & Francis Journals Auto-Holdings Collection
Beschreibungen/Notizen
CXCR1 and CXCR2 signaling play a critical role in neutrophil migration, angiogenesis, and tumorigenesis and are therefore an attractive signaling axis to target in a variety of indications. In human, a total of seven chemokines signal through these receptors and comprise the ELR
CXC chemokine family, so named because of the conserved ELRCXC N-terminal motif. To fully antagonize CXCR1 and CXCR2 signaling, an effective therapeutic should block either both receptors or all seven ligands, yet neither approach has been fully realized clinically. In this work, we describe the generation and characterization of LY3041658, a humanized monoclonal antibody that binds and neutralizes all seven human and cynomolgus monkey ELR
CXC chemokines and three of five mouse and rat ELR
CXC chemokines with high affinity. LY3041658 is able to block ELR
CXC chemokine-induced Ca
mobilization, CXCR2 internalization, and chemotaxis
as well as neutrophil mobilization
without affecting other neutrophil functions. In addition to the
and
activity, we characterized the epitope and structural basis for binding in detail through alanine scanning, crystallography, and mutagenesis. Together, these data provide a robust preclinical characterization of LY3041658 for which the efficacy and safety is being evaluated in human clinical trials for neutrophilic skin diseases.